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Pyrrole–imidazole (PI) polyamides are small synthetic
molecules that recognize and attach to the minor groove
of DNA, thereby inhibiting gene transcription by blocking
transcription factor binding. These derivatives can act as
gene silencers inhibiting target gene expression under
stimulatory conditions such as disease. To evaluate PI
polyamides as treatments for the progression of renal
diseases, we examined morphological effects,
pharmacological properties, and the specificity of PI
polyamides targeted to the transforming growth factor
(TGF)-b1 promoter during salt-induced hypertensive
nephrosclerosis in Dahl salt-sensitive rats. The targeted PI
polyamide markedly reduced glomerulosclerosis and
interstitial fibrosis without side effects. PI polyamide
significantly decreased expression of TGF-b1 and extracellular
matrix in the renal cortex. Microarray analysis found that only
3% of the transcripts were affected by PI polyamide, but
this included decreased expression of extracellular matrix,
TGF-b1-related cytokines, angiogenic, and cell stabilizing
factors, proteinases, and renal injury-related factors. Thus,
targeted PI polyamides are potential gene silencers for
diseases not treatable by current remedies.
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As there have been no effective medicines for progressive
renal diseases, gene therapy is now being considered as an
attractive therapeutic strategy. A number of studies identified
transforming growth factor (TGF)-b1 as a critical factor in
kidney diseases, such as glomerulosclerosis1 and mesangial
proliferative glomerulonephritis.2,3 In the progressive glo-
merulosclerosis and interstitial fibrosis associated with
hypertensive renal sclerosis and diabetic nephropathy,
TGF-b1 caused an increase in the progressive deposition of
extracellular matrix (ECM) proteins.4 Recent studies have
shown that TGF-b1 induced epithelial–mesenchymal transi-
tion. Epithelial–mesenchymal transition-induced accumula-
tion of myofibroblasts and the subsequent tubular atrophy
are considered key determinants of the glomerular sclerosis
and interstitial fibrosis.5
Pyrrole–imidazole (PI) polyamides are powerful gene-
regulating compounds, which can inhibit DNA–protein
interaction by binding to the minor groove of double-helical
DNA with high affinity and sequence specificity.6–9 PI
polyamides are small synthetic molecules composed of the
aromatic rings of N-methylpyrrole and N-methylimidazole
amino acids. Various types of sequence-specific PI poly-
amides have been developed to control gene expression.10
DNA recognition depends on a code of side-by-side pairing
of pyrrole and imidazole in the minor groove. A pairing of
imidazole opposite pyrrole targets the G–C base pair, and PI
targets the C–G base pair. Pyrrole–pyrrole degenerately targets
T–A and A–T base pairs.9 Interfering with DNA–protein
interfaces using PI polyamides may inhibit the initiation of
gene transcription and modulate target gene induction. PI
polyamides may therefore be a new transcriptional gene
regulating agents for the treatment of diseases.
We designed PI polyamide targeted to the consensus
activator protein-1 (AP-1)-binding site on the TGF-b1
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promoter and demonstrated that the PI polyamides showed
strong, fast, and specific binding to the target oligonucleo-
tide, and inhibited TGF-b1 promoter activity and TGF-b1
expression in the mesangial cells.11,12 In the Dahl salt-
sensitive (Dahl-S) rats after high-salt (HS) loading for
2 weeks, the PI polyamide reduced TGF-b1 expression in
the renal cortex but the histology of renal damage caused by
hypertension was not observed in these assays.
The current study was undertaken for two objectives:
first, to evaluate PI polyamides as medicines according to
morphological effects, pharmacological properties, specificity,
and global effects of PI polyamide to TGF-b1 in the progress
renal injury; and second, to find the novel factors and
mechanisms in TGF-b1-related renal injury by the transcrip-
tional downregulation of TGF-b1 with the PI polyamide.
RESULTS
Distribution of polyamide 2 in chromosomal DNA and kidney
In this study, we have designed two kinds of PI polyamide to
target downstream (polyamide 1) and upstream (polyamide 2)
of the AP-1-binding site on the TGF-b1 promoter (Figure 1a).
The distribution of fluorescein isothiocyanate (FITC)–
polyamide 2 in the kidney at day 1, 7, and 14 after intravenous
administration is shown in Figure 1b. FITC–PI polyamide was
strongly localized to almost all nuclei in the renal tubules after
1 day. At day 7 and 14, localization of FITC–PI polyamide time
dependently decreased in nuclei of renal tubules, however it still
remained in nuclei of renal tubules at day 14. The simulated
and observed plasma concentrations of polyamide 2 are shown
in Figure 1c. The average plasma concentrations of polyamide 2
after the administration of 1mg every 3 and 2 days were 0.18
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Figure 1 | Structure of the synthetic pyrrole–imidazole polyamides targeted to transforming growth factor-b1 promoter,
and distribution and concentration of pyrrole–imidazole polyamide. (a) Polyamide 1 was designed to bind downstream of the activator
protein-1-binding site. Polyamide 2 was designed to bind upstream of the activator protein-1-binding site. (b) Distribution of fluorescein
isothiocyanate (FITC)–polyamide 2 in the rat kidney at days 1, 7, and 14 after injection. FITC–polyamide 2 (1mg) was injected intravenously.
Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI; original magnification  200). (c) Simulated and observed plasma
concentration–time profiles of polyamide 2 administered at 1mg every 2 or 3 days. The simulation was performed using the
pharmacokinetic model of polyamide 2 using an additive error model. The arrow heads distinguish the glomerulus from nephrotubules.
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and 0.28mg/ml, respectively. The observed concentrations of
polyamide 2 were included into 95% prediction interval
obtained by a Monte Carlo simulation. Polyamide 2 concen-
tration in plasma did not accumulate after the multiple dose
administration.
As shown in Figure 2a and b, FITC–polyamide 2 binding
to both nuclear and chromosomal DNA observed in live
HeLa cells indicated its fast cellular uptake and intracellular
transport within 15min. It is well established that the
strength of fluorescence of 4’,6-diamidino-2-phenylindole
(DAPI) and quinacrine compounds generally reflects the
relative dAþdT contents. We found that the binding profile
of polyamide 2 was highly similar to that of DAPI (Figure 2c
and d). However, certain chromosomal regions showed
differential affinities to polyamide 2 and DAPI (Figure 2d).
Polyamide 2 did not bind to chromosomal DNA as intensely
as DAPI on the Carnoy’s-fixed slides (Figure 2e).
Effects of PI polyamides on hypertensive nephrosclerosis
Morphological effects of PI polyamides to TGF-b1 on
glomerulosclerosis and interstitial fibrosis in renal cortex
are shown in Figures 3a and b, respectively. There was no
glomerular injury and no interstitial fibrosis in Dahl-S rats
on a low-salt (LS) diet. The renal cortex of Dahl-S rats on a
FITC FITC FITC
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Figure 2 |Binding of pyrrole–imidazole polyamide in chromosomal DNA. (a) HeLa cells pulse-labeled with fluorescein isothiocyanate
(FITC)–polyamide 2, were washed with spent medium and harvested for cytogenetic preparation. (b) HeLa cells pulse-labeled with
FITC–polyamide 2, were washed with spent medium, cultured for 6 h including 2 h colcemid treatment, and harvested. (c) HeLa cells pulse
labeled with FITC–polyamide 2, were washed with spent medium and harvested for cytogenetic preparation. (d) FITC–polyamide 2 and 4’,6-
diamidino-2-phenylindole (DAPI)-labeled chromosomes from the preparation shown in (c). Black bars represent chromosomal regions that
show distinctly different binding affinity for polyamide 2 and DAPI. Red bar indicates the position of the satellite body on chromosome 14.
(e) Chromosomes were fixed with Carnoy’s solution, air dried, stained with FITC–polyamide 2, and counterstained with DAPI.
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HS diet showed severe damage to the glomeruli with sclerotic
changes. Glomerular capillaries were filled with matrix
material. Polyamide 2 markedly reduced glomerulosclerosis
in a dose interval-dependent manner. The interstitium also
showed severe fibrosis in the renal cortex of HS rats.
Polyamide 2 considerably reduced this interstitial fibrosis.
Polyamide 1 did not ameliorate the renal sclerotic changes.
The glomerular injury score and the tubulointerstitial injury
score were significantly higher in the renal cortex of HS rats
than LS rats. Glomerular injury score and tubulointerstitial
injury score were significantly decreased in HS rats with
polyamide 2 treatment (Figure 3c and d).
Effects of PI polyamides on physical findings and urinary
factors
Polyamide 1 and 2 did not affect the changes in body weight
and food consumption of HS rats (Figure 4a and d). Systolic
blood pressure was remarkably increased in HS rats
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Figure 3 | Effects of salt-sensitive hypertension and treatments with pyrrole–imidazole polyamides on glomerular structure
and tubulointerstitial fibrosis after 4 weeks. (a) Glomeruli were stained with periodic acid-Schiff (original magnification  400).
(b) Renal cortex interstitium was stained with Masson’s trichrome stain (original magnification  200). (c) Glomerular injury score in Dahl
salt-sensitive rats. Dahl salt-sensitive rats were fed a low-salt (LS; open columns) or high-salt (HS; black columns) diet. Dahl salt-sensitive rats fed a HS
diet also received 1mg of polyamide 1 every 2 days (gray columns), or polyamide 2 every 2 (narrow diagonal columns) or 3 days (broad diagonal
columns) for 4 weeks. For semiquantitative evaluation of the glomerular matrix, 100 glomeruli in each specimen were examined randomly, and
lesion severity was graded from 0 to 4, according to the percentage of each glomerulus occupied by mesangial matrix. The severity was estimated
and scored according to the following scheme: 0, normal; 1, involvement of up to 25% of the glomerulus; 2, involvement of 25–50% of the
glomerulus; 3, involvement of 50–75% of the glomerulus; or 4, involvement of 75–100% of the glomerulus. Glomerular injury score was obtained by
the following formula: ((0 n0)þ (1 n1)þ (2 n2)þ (3 n3)þ (4 n4))/100. (d) Tubulointerstitial injury score score in the renal cortex. For
semiquantitative evaluation of the tubulointerstitial area, 20 areas of renal cortex were selected randomly. The percentage of each area that
showed sclerofibrotic change was estimated and assigned a score of 0, normal; 1, involvement of less than 10% of the area; 2, involvement of
10–30% of the area; 3, involvement of 30–50% of the area; 4, involvement of more than 50% of the area. Tubulointerstitial injury score was
calculated as ((0 n0)þ (1 n1)þ (2 n2)þ (3 n3)þ (4 n4))/20. *Po0.05 compared with LS rats. wPo0.05 compared with HS rats.
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compared with LS rats but both PI polyamides had no affect
on changes in systolic blood pressure (Figure 4b). Urine
volume was markedly increased in HS rats but both PI
polyamides had no affect on changes in urine volume (Figure
4c). Urinary protein and N-acetyl-b-D-glucosaminidase
(NAG) were significantly increased in HS rats. Polyamide 2
reduced the increased urinary protein and NAG in HS rats in
a dose interval-dependent manner. Polyamide 1 did not affect
the urinary protein and NAG (Figure 4e and f).
Effect of PI polyamides on the expression of
TGF-b1-related factors
Effects of treatment of PI polyamides on the expression of
TGF-b1, connective tissue growth factor, collagen type 3 a1,
and fibronectin mRNAs in the renal cortex are shown in
Figure 5a. The abundance of these mRNAs was significantly
higher in HS rats than in LS rats. Polyamide 2 significantly
decreased the expression of these mRNAs in HS rats.
Polyamide 1 did not affect these expressions.
Urinary excretion of TGF-b1 protein was significantly
higher in HS rats than in the LS rats (Figure 5b). Polyamide 2
significantly decreased urinary excretion of TGF-b1 protein
in HS rats. In addition, TGF-b1 immunostaining of
glomeruli and tubules in HS rats was stronger than in the
LS rats (Figure 6). Polyamide 2 considerably reduced TGF-b1
staining of glomeruli and tubules in HS rats. Polyamide 1 did
not affect the TGF-b1 protein expression.
Microarray analysis for effects of polyamide 2
To evaluate global effects and specificity of PI polyamide to
TGF-b1, we determined the expression of over 30 000
transcripts by microarrays of the renal cortex after the
treatment with polyamide 2. When compared with HS rats,
polyamide 2 affected the 853 transcripts two fold (Po0.05),
which represents 3% of the interrogated transcripts on the
Rat genome 230 2.0 array (Figure 7a). In all, 472 transcripts
were downregulated by polyamide 2. Polyamide 2
downregulated 9 out of 681 growth factor transcripts, 11
out of 685 cytokine transcripts, and 8 out of 397 ECM
transcripts on these array plates. We searched for AP-1-
binding sites on about 3000 nucleotides upstream of each
genomic region with TFSEACH (http://mbs.cbrc.jp/research/
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Figure 4 | Effects of pyrrole–imidazole polyamides on physical findings and urinary factors. Changes in body weight, (a) systolic
blood pressure, (b) urinary volume, (c) food consumption at day 27, (d) urinary protein, (e) urinary N-acetyl-b-D-glucosaminidase (f) in
Dahl salt-sensitive rats after treatments with pyrrole–imidazole polyamides. Dahl salt-sensitive rats were fed a low-salt (LS; open circles,
open columns) or high-salt (HS; open squares, black columns) diet. HS rats fed a HS diet also received 1mg of polyamide 1 every 2 days
(open rhombus, gray columns), or polyamide 2 every 2 (open triangles, narrow diagonal columns) or 3 days (filled triangles, broad diagonal
columns) for 4 weeks. *Po0.05 compared with LS rats. wPo0.05 compared with HS rats.
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db/TFSEARCH.html).13 Among these downregulated genes,
four genes had common sites of AP-1 binding and possible
polyamide 2-binding sites (Supplementary Tables S1–S3
online).To investigate TGF-b1-associated novel molecules in
renal injury by transcriptional downregulation of TGF-b1
with polyamide 2, we picked up molecules whose expression
was higher in HS rats than in LS rats and were decreased with
polyamide 2 by at least two fold (Po0.05) (Table 1). They
were classified as ECM, TGF-b1-related cytokines, angiogenic
factors, cell proliferative factors, cell stabilizing factors,
proteinases, renal injury-related factors, and unknown
functional factors. Expression of these unknown mRNAs
was significantly higher in HS rats than LS rats. Finally,
polyamide 2 treatment significantly decreased these mRNA
expressions in HS rats (Figure 7b).
DISCUSSION
In the post-genome area, the complete human genome
sequence has been identified and many diseases can be
understood at the DNA sequence level. Various nucleic acid
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Figure 5 | Effect of pyrrole–imidazole polyamides on
expression of transforming growth factor (TGF)-b1-related
factors. (a) The mRNA expression of TGF-b1, connective tissue
growth factor (CTGF), collagen type 3 a1, and fibronectin in the
renal cortex. (b) The urinary excretion of TGF-b1 protein in Dahl
salt-sensitive rats. Dahl salt-sensitive rats were fed a low-salt
(LS; open columns) or high-salt (HS; black columns) diet. Dahl
salt-sensitive rats fed a HS diet also received 1mg of polyamide 1
every 2 days (1, gray columns), or polyamide 2 every 2 (2, narrow
diagonal columns) or 3 days (2, broad diagonal columns) for 4
weeks. *Po0.05 compared with LS rats. wPo0.05 compared with
HS rats.
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Figure 6 | Immunofluorescence analysis of transforming
growth factor-b1 in the renal cortex. Sections were generated
and incubated with a monoclonal antibody to transforming
growth factor-b1, and a fluorescein isothiocyanate (FITC)-
conjugated polyclonal goat anti-mouse antbody. Nuclei were
stained with Hoechst 33342 (original magnification  400).
Abbreviations: HS, high salt; LS, low salt.
Kidney International (2011) 79, 46–56 51
H Matsuda et al.: PI polyamide targeting TGF-b1 for renal injury o r ig ina l a r t i c l e
compounds, such as small interfering RNA, are used for the
control of specific gene expression. As these compounds are
easily degraded by nucleases in vivo, drug delivery systems are
important to target internal organs. PI polyamides are
completely resistant to the biological degradation induced
by nucleases. PI polyamides are cell-permeable and easily
enter into the nuclei. Vector-assisted delivery systems are not
required. Therefore, PI polyamides may be more applicable
as novel gene therapeutic agents than nucleic acid
medicines.14
To evaluate side effects of the PI polyamide treatment, we
checked changes in body weight and food consumption in
Dahl-S rats. Polyamide 1 and 2 did not cause changes in body
weight and food consumption in HS rats. Polyamide 2 also
did not indicate physiological side effects, such as renal
dysfunction and liver dysfunction in rats or mice (data not
shown). PI polyamide suppresses enhancement of the target
gene by blocking the transcription factor binding and
preserves the baseline expression of the target gene, which
is an advantage of PI polyamide as the gene silencer
compared with another nucleic acid medicines, such as small
interfering RNA and ribozyme, that knockdown the target
gene. Thus, suppression of gene expression by PI polyamides
may be more efficient in the treatment of chronic non-
malignant diseases. After the pharmacokinetics of PI
polyamides in the body after systemic administration, Harki
et al.15 demonstrated via positron emission tomography that
PI polyamides were mainly excreted through the liver. We
have precisely evaluated the pharmacokinetics of PI poly-
amides in rats after intravenous administration. The
cumulative urinary and biliary excretions of PI polyamides
for 24 h were 5% of the administered dose and not detected,
respectively, suggesting that they remain in the body and are
distributed to deep compartments in organs.16 In this study,
FITC–polyamide 2 strongly bound to the nucleus in renal
tubules for 7 days. Furthermore, we simulated the plasma PI
polyamide concentrations to predict the effective dosage.
The simulated average plasma concentrations of polyamide
2 were near the values of the effective concentration in an
in vitro assay12 and these simulations might make the clinical
application easy to understand.
Best et al.17 reported that FITC–PI polyamide exhibits
good nuclear uptake in a wide variety of cell lines depending
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Figure 7 |Genome-wide expression analysis and effects of
pyrrole–imidazole polyamides on the expression of
transforming growth factor-b1-associated novel molecules.
(a) Global effects on transcripts interrogated by using a rat
genome 230 2.0 array. Each gene was normalized to the average
measurements of that gene in the high-salt (HS) rat chips to
enable comparison of relative changes in gene expression levels
between different conditions. Signal and detection flags were used
as quality controls. Only genes with a minimum signal intensity of
500, a detection flag present, or that were marginal in both
replicates in at least one of the comparison conditions, and
possessing a twofold or higher change in gene expression were
used for further assay. Venn diagrams representing transcripts
down- and upregulated (fold changeX2.0, Po0.05) by HS loading
or polyamide 2. Numbers inside the intersections represent
transcripts changed in renal sclerosis and affected by the
polyamide 2 treatment. The 853 transcripts affected by polyamide
2. The 297 transcripts increased by HS loading compared with
low-salt (LS) rats and ameliorated by polyamide 2 in HS rats. The
285 transcripts decreased by HS loading compared with LS rats
and ameliorated by polyamide 2 in HS rats. (b) The mRNA
expression of transforming growth factor-b1-associated novel
molecules in renal injury in Dahl-S rats. Dahl salt-sensitive rats
were fed a LS (open columns) or HS (black columns) diet. Dahl
salt-sensitive rats fed a HS diet also received 1mg of polyamide 1
every 2 days (1, gray columns), or polyamide 2 every 2 (2, narrow
diagonal columns) or 3 days (2, broad diagonal columns) for
4 weeks. *Po0.05 compared with LS rats. wPo0.05 compared
with HS rats. Abbreviations: C3, complement component 3, FcRg,
Fc receptor g-chain.
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on their chemical structures. In this study, we demonstrated
FITC–polyamide 2 binding to chromosomal DNA, and found
its unique binding profile in live cells. Interestingly, once
fixed by Carnoy’s solution and air dried on slides,
FITC–polyamide 2 virtually failed to bind to chromosomal
DNA. DNA is well known to assume numerous isomorphs
(for example, A, B, C, and Z forms) under various condi-
tions so DNA in the Carnoy’s-fixed chromosomes was
undoubtedly denatured and fragmented by depurination in
the acid conditions. Moreover, its native helical structure
could have collapsed or irreversibly transformed into the
C-form from application of air drying procedures to
chromatin/DNA complexes spread on slides. In the most
likely scenario, the transformed DNA configuration might
thus have remained, even when chromosomes were subjected
to renaturation protocols.18 These data thus show that a
certain stereo-specific groove structure preserved in the
native B-form DNA is a prerequisite for polyamide 2 binding
and that reversion of DNA into B-form DNA in the Carnoy’s-
fixed chromosomes failed to bind to polyamide 2. It is
well known that the geometry of the DNA helix depends
on nucleotide sequences that dictate helical configuration.
Accordingly, a preferential binding of PI polyamide in some
chromosomal regions may indicate the presence of subsets
of certain distinctive nucleotide sequences and a specific
helical configuration that was not present in other regions of
chromosomal DNA.
Dahl-S rats are useful models of human progressive renal
diseases. Dahl-S rats develop severe hypertension, glomer-
ulosclerosis, and interstitial fibrosis in response to HS
loading.19 In this experiments, TGF-b1 expression was
enhanced in the renal cortex of HS rats. TGF-b1 was
inhibited by polyamide 2 but not by polyamide 1, even
though polyamide 1 was designed to bind the AP-1 site in a
similar manner to polyamide 2. Connective tissue growth
factor, which induces the production of ECM downstream of
TGF-b1 signaling,20 and ECMs also were inhibited by
polyamide 2 but not by polyamide 1. Control HS rats
showed severe glomerulosclerosis and interstitial fibrosis.
Chronic inhibition of TGF-b1 using polyamide 2 markedly
ameliorated both glomerulosclerosis and interstitial fibrosis
without a reduction in blood pressure. Polyamide 2
significantly reduced tubulointerstitial fibrosis and urinary
NAG excretion. In outer medulla of kidney from HS rats,
there were also severe damages, such as fibrosis and cast
deposition. The treatment of polyamide 2 prevented these
microscopically observed tubular degenerations. Whereas
polyamide 1 did not ameliorate the glomerulosclerosis and
interstitial fibrosis. It is possible that different target
sequences of polyamide 1 and polyamide 2 on TGF-b1
promoter may induce the different efficiency. The TGF-b1
promoter contains the sequence 50-TGAGTCA-30, which
resembles the consensus AP-1-binging site. On this site,
polyamide 1 covered the downstream 50-AGTCA-30 and
polyamide 2 covered the upstream 50-TGAG-30. The majority
of AP-1 site-binding transcription factors recognized the
conserved common-binding sequences, TGA, in the 50 part of
the AP-1-binding site. In fact, PI polyamide to the lectin-like
oxLDL receptor-1 was designed for the front part of
Table 1 | Transcripts increased in the renal cortex of high-salt
rats compared with low-salt rats and decreased after the
transcriptional downregulation by polyamide 2
Accession no. Gene name
Fold
increase
Fold
decrease
Angiogenesis
NM_199115 Angiopoietin-like 4 13.91 –8.82
NM_053595 Placental growth
factor
3.48 7.15
NM_001107857 Eph receptor B6 5.99 3.14
NM_001106325 Endosialin 2.35 2.85
Cell proliferation
NM_133617 Megsin 5.81 3.27
Cell stabilizer
NM_001012022 Claudin 4 7.87 6.48
NM_012580 Heme oxygenase-1 3.82 2.64
NM_019217 Microtubule-
associated
protein 1b
3.05 3.09
NM_031700 Claudin 3 2.72 2.99
Cytokine
NM_133311 Interleukin-24 8.2 3.72
NM_012602 Mucin 1 5 3.26
NM_013180 Integrin b4 3.46 3.28
NM_053629 Follistatin-like 3 2.94 2.75
Extraceller matrix
NM_021760 Collagen type V a3 9.8 5.77
NM_053817 Neurexin 3 4.67 5.37
XM_223087 Laminin b3 6.9 4.88
XM_213902 Lamimin g2 5.75 4.78
NM_053861 Tenascin C 16 4.49
NM_172333 Collagen triple helix
repeat containing 1
9.43 3.66
NM_001107189 Tenascin N 12.02 3.39
NM_053304 Collagen type 1 a1 4.2 3.36
NM_019143 Fibronectin 1 5.1 2.85
Proteinase
NM_001008724 Fibrinogen a 9.9 4.21
NM_012532 Ceruloplasmin 6.54 3.34
NM_053819 Tissue inhibitor of
metallopeptidase 1
5.52 3.28
Renal injury
NM_173149 Kidney injury
molecule 1
13.26 5.09
NM_001024242 Cathepsin W 2.86 4.1
NM_130741 Lipocalin 2 6.9 3.54
NM_053021 Clusterin 2.54 2.09
Unknown
XM_232745 Stratifin 9.71 4.54
NM_139325 Enolase 2g 3.29 3.38
NM_053843 Immunoglobulin G
Fc receptor
2.89 2.84
NM_030839 Synaptotagmin XIII 3.22 2.83
NM_016994 Complement
component 3
3.1 2.78
NM_022401 Plectin 1 2.4 2.67
Fold increase: high-salt rats/low-salt rats. Fold decrease: polyamide 2/high-salt rats.
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the AP-1-binding site, and showed specific inhibition
of the target gene.21 These results may thus that 50 parts of
the AP-1-binding site are more important and that PI
polyamides work when they just cover the critical sequences
that bind AP-1 transcription factors to a gene promoter.
To evaluate specificity of polyamide 2, we performed
microarray analysis in the renal cortex after polyamide
2 treatment. Polyamide 2 affected only 3% of the 430 000
interrogated transcripts in HS rats. We performed further
analysis of promoter structure in these inhibited genes for the
presence of AP-1 sites and polyamide 2-binding sites. There
were only a few common sites of AP-1 and polyamide
2 binding in the 3 kb upstream of the transcription initiation
sites in these inhibited genes. These four genes were TGF-b1-
related molecules22–27 and affected by HS loading, indicating
the depressant action of TGF-b1 by polyamide 2. Only cell
division cycle-associated 7 had one AP-1-binding site, which
was covered at the 50 part of the consensus AP-1 site, 50-TGA-
30, by polyamide 2. We thus assumed that polyamide 2
particularly silenced the TGF-b1 gene at the transcription level
because it was designed to recognize both the AP-1-binding site
and unique DNA sequences of the TGF-b1 promoter.
To find the novel molecules and mechanisms of TGF-b1-
associated renal sclerosis from microarray analysis, we picked
up transcripts that had increased in HS rats and decreased
after the transcriptional downregulation by polyamide 2.
Stratifin is a molecule that induces keratinocyte differentia-
tion and numerous crucial intracellular functions such as
cell cycle and apoptosis, cell survival, and protein folding
and processing.28 Stratifin stimulates the expression of
matrix metalloproteinase-1 in fibroblasts and this effect can
be abrogated by TGF-b1.29 As there has been no report of
stratifin being present during renal sclerosis, it may be a
novel molecule in renal injury. Increases in enolase-2g in HS
rats are interesting because it is a marker of renal cell
carcinoma,30 indicating some role of enolase-2g in the renal
sclerosis. Complement component 3 (C3) and immunoglo-
bulin G Fc receptor g-chain (FcRg) may be also associated
with the renal sclerosis. Complement activation and FcRg
contribute to tissue injury in various forms of glomerulo-
pathy.31,32 We recently reported that C3 caused mesangial
cells to convert to the synthetic phenotype and aggravated a
glomerular injury.33 Finally, synaptotagmins represent a
family of putative vesicular trafficking proteins.34 Plectin-1
has been known to be distributed in visceral epithelial cells of
glomeruli.35 Synaptotagmin 13 and plectin-1 may contribute
to TGF-b1-related renal sclerosis.
In conclusion, PI polyamide easily entered into the
nucleus and strongly bound chromosomal DNA in cultured
cells. It was localized to almost all nuclei in renal tubules for
7 days. The treatment with polyamide 2 for 4 weeks markedly
reduced renal sclerosis in HS rats without side effects.
Polyamide 2 suppressed the TGF-b1 gene transcriptionally
and specifically. PI polyamides could serve as gene silencing
medicines for diseases that are not treatable with current
medicines.
MATERIALS AND METHODS
This study conformed to the standards of the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes
of Health (publication no. 85-23, revised 1996) and approved by
Nihon University Institutional Animal Care and Use Committee
committee.
Synthesis of PI polyamides targeted to TGF-b1
Polyamide 1 and 2 targeted to rat TGF-b1 were developed to bind
across the boundary of the consensus AP-1-binding site (2303 to
2297 nucleotides upstream of ATG) and the unique DNA
sequences of the rat TGF-b1 promoter as described in Matsuda
et al.12 (Figure 1a). Numbering was set at the start of the open
reading frame as þ 1.36 PI polyamides were synthesized according to
previously described methods37 and were purified by high-
performance liquid chromatography.
Distribution of FITC–polyamide 2 in the chromosomal DNA
and kidney
FITC–polyamide 2 binding was examined in two ways. First,
asynchronous cultures of HeLa cells were pulse labeled for 15 and
30min with 10 mM of the compound in a light-proof incubator at
37 1C. The cultures were washed and incubated for 6 h with the last
2 h in the presence of 0.06 mg/ml of colcemid.38 The cells were
harvested, treated with chromosomal hypotoxic solution, and then
fixed with Carnoy’s solution. The cells were spread on slide glasses
and then counterstained with DAPI. Images were captured using the
fluorescence in situ hybridization (FISH) signal-detection software
(Applied Spectral Imaging, Vista, CA, USA), as described pre-
viously.39 Second, logarithmically growing cells of the HeLa cell line
were treated for 2 h with 0.06mg/ml of Colcemid, fixed with
Carnoy’s solution, and then air dried on slide glasses. The slides were
either immediately treated for 30min with 10mM FITC–polyamide 2
at 37 1C or subjected to RNase–pepsin digestion to remove RNA and
chromatin proteins associated with chromosomes, and then reacted
for 30min at 37 1C with 10 mM of FITC–polyamide 2 in phosphate-
buffered saline or 2 sodium chloride/sodium citrate hybridization
buffer. Chromosome slides were analyzed as described elsewhere.39
To evaluate the kidney distribution of PI polyamides, 1mg of
FITC–polyamide 2 was injected into Wistar rats via the tail vein.
After 1, 7, and 14 days, the kidneys were removed and frozen
specimens were made and viewed.
Pharmacokinetic simulation
Pharmacokinetic simulations of polyamide 2 administered at 1mg
every 2 or 3 days for 4 weeks were performed using a slightly
modified pharmacokinetic model as described previously15 using
NONMEM var. 6 (ICON development solutions, MD, USA). The
residual error model was assumed an additive error model. The
average plasma polyamide 2 concentrations were calculated by
the area under the concentration-time curves between 0 and 27 days,
divided by 27 days.
In vivo experimental design
Male Dahl-S rats (7-week old; CLEA Japan, Tokyo, Japan) were used
in this study. Rats were divided into two groups and were fed a LS
(0.3% NaCl) or HS (8% NaCl) diet (both from Oriental Yeast,
Tokyo, Japan) ad libitum for 4 weeks. At the same time, 1mg of
polyamide 1 was dissolved in 200 ml of 0.1% acetic acid and injected
via the tail veins of HS rats every 2 days from day 1 for 4 weeks.
Polyamide 2 was injected every 2 or 3 days from day 1 for 4 weeks.
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Control rats were injected with 200 ml 0.1% acetic acid. Systolic
blood pressure was measured by the tail-cuff method. Urine was
collected for 24 h every 9 days. Urinary protein excretion and NAG
activity were determined with a Bio-Rad protein assay kit (Bio-Rad,
Hercules, CA, USA) and NAG test pack (Shionagi, Osaka, Japan). To
determine the plasma polyamide 2 concentration, blood samples were
collected from the heart at 28 days. The plasma polyamide 2
concentrations were measured by an ACQUITY Ultra Performance LC
system (Nihon Waters KK, Tokyo, Japan) using an ACQUITY UPLC
HSS T3 column (1.8mm, 2.1 50mm; Nihon Waters KK) according
to the reported methods40 with slight modification. The multiple
reaction monitoring transition for polyamide 2 was m/z 8344165.
Renal morphology
After 3-mm paraffin sections were stained with periodic acid-Schiff
reagent or Masson’s trichrome stain for semiquantitative evaluation,
glomerular injury score, and tubulointerstitial injury score were
determined as described previously.41,42
Microarray analysis and determination of mRNA expression
Total RNAwas extracted from renal cortex by using RNEasy Mini kit
(Qiagen, Valencia, CA, USA). In vitro transcription products
were prepared from 5 mg of total RNA and hybridized to Rat
genome 230 2.0 array (Affymetrix, Santa Clara, CA, USA) according
established protocols. Affymetrix data were imported into Gene-
spring GX 7.3.1 (Agilent technologies, Foster City, CA, USA) and
analyzed to determine expression profiles.
To quantify mRNA expressions, we performed real-time PCR
with either SYBR-green or TaqMan detection. Real-time PCR was
performed with TaqMan Universal Master Mix, SYBR Green Master
Mix (for Stratifin) and an ABI 7500 sequence detector (Applied
Biosystems, Foster City, CA, USA) according to the manufacturer’s
instructions.
Measurement of TGF-b1 protein
TGF-b1 protein levels in urine were determined by enzyme
immunoassay (TGF-b1 Emax ImmunoAssay System; Promega,
Madison, WI, USA) as described previously.43 Urine samples from
Dahl-S rats for 4 weeks were collected for 24 h and diluted 1:1000 in
sample buffer.
TGF-b1 immunofluorescence
Unstained 3-mm-thick paraffin sections of renal cortex were depar-
affinized, hydrated, and treated with 10mM sodium citrate buffer (pH
6.0) for 15min at 96 1C. Sections were blocked with Serum Blocking
Reagent G (R&D Systems, Minneapolis, MN, USA) for 15min. The
slides were then incubated with diluted primary Ab (Monoclonal
mouse Ab to TGF-b; R&D Systems) for 16h at 4 1C, washed in
phosphate-buffered saline, and incubated with FITC-conjugated
polyclonal goat-anti-mouse Ab (Dako, Carpinteria, CA, USA) for
30min at room temperature. After being washed in phosphate-buffered
saline, sections were incubated with Hoechst 33342 and viewed.
Statsistical analysis
Values are reported as mean±standard error (s.e.m.). Student’s
t-test was used for unpaired data. Two-way analysis of variance
and Duncan’s multiple range tests were also used. Po0.05 was
considered statistically significant.
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